Welcome to our dedicated page for Cassava Sciences news (Ticker: SAVA), a resource for investors and traders seeking the latest updates and insights on Cassava Sciences stock.
Cassava Sciences, Inc. (SAVA) is a clinical-stage biotechnology company pioneering Alzheimer's disease research through therapeutic candidate simufilam and diagnostic tool SavaDx. This page aggregates official press releases, regulatory updates, and material event announcements directly from the company and verified sources.
Investors and researchers will find timely updates on Phase 3 clinical trial progress, FDA communications, intellectual property developments, and peer-reviewed study publications. Our curated feed ensures access to SAVA's critical milestones in drug development and diagnostic innovation without promotional commentary.
Key content categories include clinical trial results, partnership announcements with research institutions, financial disclosures related to R&D funding, and scientific presentations at major medical conferences. All materials are organized chronologically to track the company's evolving research narrative.
Bookmark this page for streamlined monitoring of Cassava Sciences' advancements in Alzheimer's therapeutics. For comprehensive analysis, cross-reference updates with SEC filings and scientific publications linked in source materials.
Cassava Sciences (Nasdaq: SAVA) announced a proposed underwritten public offering of its common stock, subject to market conditions. The offering will include a 30-day option for underwriters to purchase an additional 15% of the shares. Proceeds are intended to fund a Phase 3 clinical program for sumifilam, their lead candidate for Alzheimer's disease, as well as research and general corporate purposes. Cantor Fitzgerald & Co. is managing the offering. The securities are registered under a previously declared effective shelf registration statement.
Cassava Sciences, Inc. (SAVA) reported a net loss of $1.4 million for Q3 2020, or $0.06 per share, an increase from a loss of $0.7 million ($0.04 per share) in Q3 2019. Total cash and cash equivalents stand at $24.1 million, up from $23.1 million at the end of 2019, with no debt. Net cash used in operations for the first nine months of 2020 hit $4.2 million, and the company expects to end the year with approximately $5.0 million in cash usage. R&D expenses rose to $0.4 million due to decreased NIH grant reimbursements.
Cassava Sciences (Nasdaq: SAVA) announced promising results from a Phase 2b study of sumifilam in Alzheimer’s patients. The drug demonstrated a statistically significant 33% reduction in HMGB1 levels (p<0.001) and improved blood-brain barrier integrity (p<0.05) after 28 days. These findings suggest that sumifilam may effectively address neuroinflammation and neurodegeneration associated with Alzheimer’s. The final results will be presented on November 7 at the CTAD 2020 conference, underscoring the potential for further clinical development, including a planned Phase 3 study.
Cassava Sciences (SAVA) announced that results from its Phase 2b study of sumifilam, targeting Alzheimer’s disease, will be presented at the CTAD conference on November 7, 2020. The study, funded by the NIH, showed statistically significant improvements in various CSF biomarkers and cognitive tests in Alzheimer’s patients treated with sumifilam compared to placebo. The treatment demonstrated a 98% responder rate and was safe and well-tolerated. Ongoing studies include a long-term open-label trial targeting 100 patients, with over 50% enrollment achieved.
Cassava Sciences (SAVA) announced promising results from its Phase 2b study of sumifilam for Alzheimer's disease. The drug significantly improved various biomarkers compared to placebo, achieving a response rate of 98% (p<0.05). Patients on sumifilam experienced cognitive improvements, with effect sizes ranging from 17% to 46%. The treatment demonstrated a decrease in neuroinflammation markers and was well-tolerated with no patient discontinuations. The study, funded by NIH, positions sumifilam as a potential transformative therapy for Alzheimer's, with ongoing trials planned.
Cassava Sciences, Inc. (Nasdaq: SAVA), a biotech company focused on Alzheimer’s disease, announced a conference call scheduled for September 14, 2020, at 8:30 a.m. Eastern Time. Details include a dial-in number for domestic and international callers and an audio webcast available on their website. The replay will be accessible for 90 days. Cassava aims to develop innovations for chronic neurodegenerative conditions, leveraging advanced technology and insights into neurobiology, with full rights to its Alzheimer’s research programs.
Cassava Sciences, a clinical-stage biotech company focused on Alzheimer’s disease, will present a corporate overview at the H.C. Wainwright’s 22nd Annual Global Investment Conference on September 15, 2020, at 2:30 p.m. ET. The presentation will be available via a live webcast, and a replay will be accessible for 90 days afterwards on their website. Alzheimer’s affects approximately 5.8 million people in the U.S., and the number is expected to rise significantly, highlighting the increasing burden of this condition.
Cassava Sciences, Inc. (SAVA) announced the granting of U.S. Patent No. 10,760,052 on September 1, 2020, related to inhibiting TLR4-mediated immune responses using filamin A binding molecules. This adds to their growing patent portfolio, which now includes seven issued patents extending through 2037. The company’s main drug candidate, sumifilam, aims to treat Alzheimer's disease by restoring altered filamin A function in the brain. Cassava retains worldwide rights for its developments in Alzheimer’s without royalty obligations, reinforcing its position in this critical therapeutic area.
Cassava Sciences, Inc. announced that its lead drug candidate, PTI-125, has been officially named sumifilam by the USAN Council. This investigational drug is the first of a new class targeting filamin proteins and aims to treat Alzheimer's disease. A commercial name for sumifilam will be announced later. The drug is designed as an oral therapy that restores normal function of altered filamin A in the brain, potentially addressing significant neurodegenerative challenges. Currently, no drugs exist to halt or reverse Alzheimer's pathology.
Cassava Sciences, focused on Alzheimer’s disease, reported a net loss of $1.1 million, or $0.05 per share, for Q2 2020, unchanged from the prior year's loss. Cash and cash equivalents stood at $25.3 million as of June 30, 2020. The company continues to expect a total net cash use of approximately $5.0 million for the year. Additionally, the Phase 2b study of PTI-125 is set to announce final results in September 2020, following an initial bioanalysis showing unexplained variability. The open-label study of PTI-125 has surpassed 50% enrollment. SavaDx demonstrated target engagement in preliminary studies.
